The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Qing Su
126 participants
Jun 5, 2025
INTERVENTIONAL
Conditions
Summary
The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.
Eligibility
Inclusion Criteria3
- Age 50-70 years with overweight or obesity (BMI 24kg/m2);
- At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \<7% without glucose-lowering drug therapy;
- Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
Exclusion Criteria15
- Patients with tumours;
- Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
- Severe cardiovascular disease or cardiac insufficiency;
- Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg;
- Chronic obstructive pulmonary disease;
- Chronic active hepatitis or cirrhosis;
- Chronic renal insufficiency;
- Stroke patients
- Severe haematological diseases;
- Infectious diseases;
- Mental illness;
- Other conditions that, in the opinion of the investigator, may affect the results of the study;
- Those who have used NMN or other anti-aging agents within six months.
- Premenopausal woman
- ALT, AST values are more than three times higher than the upper limit of the normal reference range
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
NMN SR tablets(1000mg/tablets) , 1 tablet daily before breakfast
Matching Placebo (tablets) once daily before breakfast
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06907329